Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification

Maki Shibata, Takashi Shigematsu, Ikuji Hatamura, Fumie Saji, Sachiko Mune, Ken Kunimoto, Yoshiyuki Hanba, Kazuhiro Shiizaki, Toshifumi Sakaguchi, Shigeo Negi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background. Vascular calcification is an important complication that worsens the prognosis for dialysis patients, although its detailed molecular mechanisms are still unknown. Methods. We produced a rat model for vascular calcification with hyperphosphatasemia and hyperparathyroidism, performing a 56 nephrectomy and providing a high-phosphorus, low-calcium diet for eight weeks. We examined mRNA obtained from the calcified aortae using microarray analysis, and searched for alterations in gene expression specifically in the calcified lesions. Results. Medial calcification was demonstrated in the abdominal aorta of 12 out of 42 hyperparathyroidism rats. In the aortae of hyperparathyroid rats with vascular calcification, the genes for heparan sulfate proteoglycans, including perlecan, were found to be down-regulated using microarray analysis and real time PCR. Immunohistochemistry also demonstrated reduced production of perlecan in the aortae of hyperparathyroid rats. Discussion. Perlecan is a major component of the vascular wall basement membrane and may play a role in protecting vascular smooth muscle cells from inflammatory cells and various toxins. It has also been reported that heparan sulfate chains may inhibit osteogenesis. Our findings indicate that perlecan may protect vascular smooth muscle cells from various factors that promote vascular calcification. Conclusions. It may be that reduced expression of perlecan in the calcified aortae of hyperparathyroid rats is a risk factor for vascular calcification.

Original languageEnglish (US)
Pages (from-to)214-223
Number of pages10
JournalRenal Failure
Volume32
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Vascular Calcification
Secondary Hyperparathyroidism
Aorta
Hyperparathyroidism
Microarray Analysis
Vascular Smooth Muscle
Smooth Muscle Myocytes
Heparan Sulfate Proteoglycans
Heparitin Sulfate
Abdominal Aorta
Nephrectomy
Basement Membrane
Osteogenesis
Phosphorus
Blood Vessels
Real-Time Polymerase Chain Reaction
Dialysis
Immunohistochemistry
perlecan
Diet

Keywords

  • Heparan sulfate proteoglycan
  • Hyperparathyroidism
  • Hyperphosphatemia
  • Perlecan
  • Vascular calcification

ASJC Scopus subject areas

  • Nephrology
  • Critical Care and Intensive Care Medicine

Cite this

Shibata, M., Shigematsu, T., Hatamura, I., Saji, F., Mune, S., Kunimoto, K., ... Negi, S. (2010). Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. Renal Failure, 32(2), 214-223. https://doi.org/10.3109/08860220903367544

Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. / Shibata, Maki; Shigematsu, Takashi; Hatamura, Ikuji; Saji, Fumie; Mune, Sachiko; Kunimoto, Ken; Hanba, Yoshiyuki; Shiizaki, Kazuhiro; Sakaguchi, Toshifumi; Negi, Shigeo.

In: Renal Failure, Vol. 32, No. 2, 03.2010, p. 214-223.

Research output: Contribution to journalArticle

Shibata, M, Shigematsu, T, Hatamura, I, Saji, F, Mune, S, Kunimoto, K, Hanba, Y, Shiizaki, K, Sakaguchi, T & Negi, S 2010, 'Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification', Renal Failure, vol. 32, no. 2, pp. 214-223. https://doi.org/10.3109/08860220903367544
Shibata, Maki ; Shigematsu, Takashi ; Hatamura, Ikuji ; Saji, Fumie ; Mune, Sachiko ; Kunimoto, Ken ; Hanba, Yoshiyuki ; Shiizaki, Kazuhiro ; Sakaguchi, Toshifumi ; Negi, Shigeo. / Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification. In: Renal Failure. 2010 ; Vol. 32, No. 2. pp. 214-223.
@article{0b4433fb064c4ae1850f4811d460e5c8,
title = "Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification",
abstract = "Background. Vascular calcification is an important complication that worsens the prognosis for dialysis patients, although its detailed molecular mechanisms are still unknown. Methods. We produced a rat model for vascular calcification with hyperphosphatasemia and hyperparathyroidism, performing a 56 nephrectomy and providing a high-phosphorus, low-calcium diet for eight weeks. We examined mRNA obtained from the calcified aortae using microarray analysis, and searched for alterations in gene expression specifically in the calcified lesions. Results. Medial calcification was demonstrated in the abdominal aorta of 12 out of 42 hyperparathyroidism rats. In the aortae of hyperparathyroid rats with vascular calcification, the genes for heparan sulfate proteoglycans, including perlecan, were found to be down-regulated using microarray analysis and real time PCR. Immunohistochemistry also demonstrated reduced production of perlecan in the aortae of hyperparathyroid rats. Discussion. Perlecan is a major component of the vascular wall basement membrane and may play a role in protecting vascular smooth muscle cells from inflammatory cells and various toxins. It has also been reported that heparan sulfate chains may inhibit osteogenesis. Our findings indicate that perlecan may protect vascular smooth muscle cells from various factors that promote vascular calcification. Conclusions. It may be that reduced expression of perlecan in the calcified aortae of hyperparathyroid rats is a risk factor for vascular calcification.",
keywords = "Heparan sulfate proteoglycan, Hyperparathyroidism, Hyperphosphatemia, Perlecan, Vascular calcification",
author = "Maki Shibata and Takashi Shigematsu and Ikuji Hatamura and Fumie Saji and Sachiko Mune and Ken Kunimoto and Yoshiyuki Hanba and Kazuhiro Shiizaki and Toshifumi Sakaguchi and Shigeo Negi",
year = "2010",
month = "3",
doi = "10.3109/08860220903367544",
language = "English (US)",
volume = "32",
pages = "214--223",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Reduced expression of perlecan in the aorta of secondary hyperparathyroidism model rats with medial calcification

AU - Shibata, Maki

AU - Shigematsu, Takashi

AU - Hatamura, Ikuji

AU - Saji, Fumie

AU - Mune, Sachiko

AU - Kunimoto, Ken

AU - Hanba, Yoshiyuki

AU - Shiizaki, Kazuhiro

AU - Sakaguchi, Toshifumi

AU - Negi, Shigeo

PY - 2010/3

Y1 - 2010/3

N2 - Background. Vascular calcification is an important complication that worsens the prognosis for dialysis patients, although its detailed molecular mechanisms are still unknown. Methods. We produced a rat model for vascular calcification with hyperphosphatasemia and hyperparathyroidism, performing a 56 nephrectomy and providing a high-phosphorus, low-calcium diet for eight weeks. We examined mRNA obtained from the calcified aortae using microarray analysis, and searched for alterations in gene expression specifically in the calcified lesions. Results. Medial calcification was demonstrated in the abdominal aorta of 12 out of 42 hyperparathyroidism rats. In the aortae of hyperparathyroid rats with vascular calcification, the genes for heparan sulfate proteoglycans, including perlecan, were found to be down-regulated using microarray analysis and real time PCR. Immunohistochemistry also demonstrated reduced production of perlecan in the aortae of hyperparathyroid rats. Discussion. Perlecan is a major component of the vascular wall basement membrane and may play a role in protecting vascular smooth muscle cells from inflammatory cells and various toxins. It has also been reported that heparan sulfate chains may inhibit osteogenesis. Our findings indicate that perlecan may protect vascular smooth muscle cells from various factors that promote vascular calcification. Conclusions. It may be that reduced expression of perlecan in the calcified aortae of hyperparathyroid rats is a risk factor for vascular calcification.

AB - Background. Vascular calcification is an important complication that worsens the prognosis for dialysis patients, although its detailed molecular mechanisms are still unknown. Methods. We produced a rat model for vascular calcification with hyperphosphatasemia and hyperparathyroidism, performing a 56 nephrectomy and providing a high-phosphorus, low-calcium diet for eight weeks. We examined mRNA obtained from the calcified aortae using microarray analysis, and searched for alterations in gene expression specifically in the calcified lesions. Results. Medial calcification was demonstrated in the abdominal aorta of 12 out of 42 hyperparathyroidism rats. In the aortae of hyperparathyroid rats with vascular calcification, the genes for heparan sulfate proteoglycans, including perlecan, were found to be down-regulated using microarray analysis and real time PCR. Immunohistochemistry also demonstrated reduced production of perlecan in the aortae of hyperparathyroid rats. Discussion. Perlecan is a major component of the vascular wall basement membrane and may play a role in protecting vascular smooth muscle cells from inflammatory cells and various toxins. It has also been reported that heparan sulfate chains may inhibit osteogenesis. Our findings indicate that perlecan may protect vascular smooth muscle cells from various factors that promote vascular calcification. Conclusions. It may be that reduced expression of perlecan in the calcified aortae of hyperparathyroid rats is a risk factor for vascular calcification.

KW - Heparan sulfate proteoglycan

KW - Hyperparathyroidism

KW - Hyperphosphatemia

KW - Perlecan

KW - Vascular calcification

UR - http://www.scopus.com/inward/record.url?scp=77749279759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77749279759&partnerID=8YFLogxK

U2 - 10.3109/08860220903367544

DO - 10.3109/08860220903367544

M3 - Article

C2 - 20199184

AN - SCOPUS:77749279759

VL - 32

SP - 214

EP - 223

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 2

ER -